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PCV32
SOCIOECONOMIC RELEVANCE OF TREATMENT OF
CHRONIC HEART FAILURE STAGE NYHA II WITH
CRATAEGUS EXTRACT WS® 1442—A PROSPECTIVE 3-YEAR
PHARMACOECONOMIC STUDY
Rychlik R1, Pfeil T1, Daniel D1, Habs M2, Klapper HG2
1Institute of Empirical Health Economics, Burscheid, Germany; 2Dr.
Willmar Schwabe Arzneimittel, Karlsruhe, Germany
OBJECTIVES: A prospective 3-year observational study has
been conducted from 1999 to 2002 to evaluate the pharma-
coeconomics of hawthorn-extract treatment of CHF at stage
NYHA II. In a cost-utility-analysis (CUA) hawthorn treatment
(crataegus extract WS® 1442 as mono- or add-on-therapy) was
compared to any other treatment option. Interim results of the
study were presented in 2001 and 2002, now the ﬁnal results 
are available. METHODS: Open, non-randomized observa-
tional cohort study with matched-pairs evaluation. The ﬁrst
cohort (Hawthorn-Cohort, HC) comprised patients receiving
hawthorn-extract therapy of CHF; in the second cohort 
(Conventional-Cohort, CC) patients with any other treatment
were observed. A number of 116 pairs were necessary for eval-
uation. For measuring HRQL the EuroQoL-5D was used.
Matching criteria were demographic factors and clinical diag-
nosis. The perspective of the German statutory health insurance
funds was applied. RESULTS: From 140 study centres 614
patients ﬁnished the study (HC: 383; CC: 231). Thereof 153
pairs could be established. Mean direct costs per year for HC
and CC amounted to 807€ (median: 511€) and 798€ (median:
525€), respectively (p = 0.905). Cost-driving factor was drug
acquisition (median HC: 287€, CC: 280€; p = 0.521). Signiﬁ-
cantly fewer prescriptions were done in HC for concomitant
ACE-inhibitors, diuretics, digitalis, and beta-blockers. The clin-
ical symptoms dyspnea and fatigue in HC were signiﬁcantly
improved in comparison to CC. During 3 years in the HC 0.240
QALYs were gained (CC: 0.234; p = 0.867). Costs per QALY
gained amounted to 10,113€ and 10,244€ for HC and CC,
respectively. CONCLUSIONS: Hawthorn extract WS® 1442
represents an effective treatment alternative in early stages of
CHF. Outcomes and costs are comparable to treatment with
ACE-inhibitors, diuretics, digitalis, and/or beta-blockers, which
are recommended by international guidelines. The symptoms
dyspnea and fatigue, which markedly affect the patients’ daily
activities, can be improved with WS® 1442.
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MODELING THE ECONOMIC IMPACT OF NEW IMPLANTABLE
DEFIBRILLATORS WITH A LONGER LIFETIME
Lamarsalle L1,Vainchtock A2, Le Heuzey JY3, Matalon C4, Hazard JR4
1GYD institut—division of IMS Health, Lyon, France; 2GYD institut—
division of IMS Health; 3Hôpital Européen Georges Pompidou;
4Guidant France SAS
OBJECTIVES: Vitality 2EL, a new implantable deﬁbrillator
(ICD), presents a major advantage: a longer lifetime increasing
delay before replacement leading to less reimplantations. This
study aims to compare direct medical costs, using this new ICD,
Vitality 2EL, versus its main competitors in France. METHODS:
The ﬁrst step was to identify among patients included into
EVADEF (French national registry of ICD-implanted patients), 
7 homogeneous groups according to age at ﬁrst implant. 
Then, within each group, we determined average ages and life
expectancies using Deale’s method and data from the French
national statistical institute (INSEE). A Markov model was built
using DATA Tree age Pro 2004 taking into account complica-
tion rates from literature. Direct medical costs were assessed
from the French health care payer’s perspective and a 2.5% dis-
count rate was applied. This model was applied to those 7
groups, per single & dual chamber deﬁbrillators (VR & DR), in
primary and secondary prevention, and for warranted period
(deﬁned by manufacturers) and projected longevity at 15%/50%
pacing. RESULTS: The model shows an average cost savings
range from 34 to 6356€ per patient with Vitality 2EL versus
competitors. CONCLUSION: Implanting a longer lifetime ICD
is clinically beneﬁcial for patients. Furthermore, we demon-
strated that it allows cost savings for health care payers.
PCV34
COST-EFFECTIVENESS OF ANTICOAGULATION WITH
BIVALIRUDIN VS. HEPARIN AND GLYCOPROTEIN INHIBITORS
IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY
INTERVENTION IN SWEDEN
Borg S1, Persson U1, Conradson TB2, Ericsson K2
1Swedish Institute for Health Economics, Lund, Sweden; 2Nycomed
Group, DK-4000 Roskilde, Denmark
OBJECTIVE: To analyse the cost-effectiveness of anticoagula-
tion with bivalirudin compared to heparin and GlycoProtein
Inhibitors IIb/IIIa (GPIs) in patients undergoing Percutaneous
Coronary Intervention (PCI) in Sweden. METHODS: As treat-
ment practice varies between hospitals, e.g. the fraction of
patients receiving GPI varies, the model analyses a patient cohort
where heparin is combined with GPIs to a variable percentage
(% GPIs) and the remaining patients receive heparin monother-
apy. The Swedish Council on Technology Assessment in Health
Care has estimated that GPIs are being used in a range of
40–50% of all PCIs. Abciximab is the only GPI with indication
for PCI in Sweden, and it was therefore used as the comparator.
Pooled data from applicable studies (REPLACE-2, EPISTENT,
ESPRIT), provided probabilities for the events; death, myocar-
dial infarction (MI), urgent revascularisation (UR) and major
and minor bleedings according to the TIMI deﬁnitions. Treat-
ment costs (year 2004) were collected for each complication
from four Swedish hospitals, and ofﬁcial drug prices from the
Swedish pharmacopeia. The model was evaluated using sto-
chastic evaluation, in a Swedish Health Care perspective, in a
30-day time frame. The modelled patient population was on
average 63 years of age, 75% male. RESULTS: Compared to a
40–50% usage of GPIs, treatment with bivalirudin reduced (p <
0.05) all complications (e.g. by 9.3 MIs, 1.9 URs, 14.4 bleedings
and 1.5 deaths in 1000 treated patients, of which 40% received
a GPI), and at the same time signiﬁcantly reduced total costs for
drugs and health care (87 SEK/patient, 95% CI 21 to 157 at
40% GPIs, or 935 SEK/patient, 95% CI 867 to 997 at 50%
GPIs). CONCLUSIONS: Treatment with bivalirudin as com-
pared to heparin and GPIs, signiﬁcantly reduced all studied com-
plications, and resulted in signiﬁcant savings in total costs of
drugs and health care in Sweden.
PCV35
ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE 
CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FOR A
COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN
MONOTHERAPY
Davies GM1,Alemao E2, Nocea G3,Yin D2, Cook JR1
1Merck & Co., Inc, Blue Bell, PA, USA; 2Merck & Co, Whitehouse
Station, NJ, USA; 3Merck, Sharp & Dohme de España, Madrid, Spain
OBJECTIVE: Assess cost-effectiveness of switching patients to
ezetimibe 10mg (EZ10) co-administration with simvastatin 
20mg (S20) versus an atorvastatin titration strategy (patients are
titrated to goal or maximum atorvastatin dose of 80mg) in CHD
and CHD equivalent patients not at goal with atorvastatin 
10mg (A10) monotherapy. Method: Decision-analytic model
